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Recurrent pregnancy loss (RPL) is defined as the 
occurrence of ≥2 consecutive pregnancy losses before 20th 
week of gestation. This stressful problem is encountered in 
about 2% of women attempting pregnancy. Known causes 
of RPL include autoimmune disorders (~20%), endocrine 
factors (17-20%), anatomic abnormalities (10-15%), 
genetic abnormalities (2-5%) and infectious factors (0.5-
5%). In an ample number of cases, mounting to 40-50%, 
however, the causes remain indefinite (Abu-Asab et al., 
2011; Lavigne et al., 2005; Ford and Schust, 2009). 
In the last two decades, heritable and/or acquired 
thrombophilias have strongly emerged as a possible 
etiology for RPL. Thrombophilia can be defined as a 
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ABSTRACT 
Background: This study was conducted in order to determine the relationship between the common polymorphisms 
in β-fibrinogen -455 G/A (rs1800790) and Integrin beta-3 T196C (PLA1/A2, rs5918) and recurrent pregnancy loss 
(RPL) in a group of Palestinian women residing in Gaza strip. 
Methods: The study presented here is a retrospective association study with a case-control design. The study 
population consisted of 102 women who suffered from RPL and 97 healthy women matched for age and without a 
previous history of RPL. DNA extracted from blood samples of all subjects was investigated for the β-fibrinogen (-
455 G>A) and Integrin beta-3 (PLA1/A2) polymorphisms using PCR-RFLP and PCR-SSP, respectively.  
Results: The study revealed that β–fibrinogen -455G/A minor allele frequency (allele A) and its homozygous 
genotype (AA) were not significantly different between the RPL and the control groups. Likewise, there was no 
significant difference in the distribution of the ITGB-3 variant allele (PLA2) or PLA2/A2 genotype between the two 
groups. β–fibrinogen AA genotype was evident in 3.9 % of the patients and in 4.1% of the controls (P-value = 0.94). 
The frequency of PLA2/A2 was observed in 2.0 % of the patients and in 2.1% of the controls (P-value = 0.96). 
Conclusion: Results of the present study indicate that there is no significant association between the β–fibrinogen  
(455 G>A) or Integrin beta-3 (PLA1/A2) common polymorphisms and the occurrence of RPL in Gaza strip. This non-
significant relation indicates that the investigated polymorphisms do not constitute a tangible risk for RPL in our 
population. Therefore, it is not recommended to consider these two polymorphisms when screening for inherited 
thrombophilia in Gaza strip. 
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predisposition to form thrombi inappropriately. Marked 
thrombocytosis, increased platelet aggregation, increased 
activity levels of coagulation factors, and excess plasma 
levels of fibrinolytic inhibitors may all enhance thrombosis. 
Fibrinogen (Factor I) is a glycoprotein that participates in 
the coagulation cascade. Fibrinogen is composed of three 
pairs of polypeptide chains (named α, β and γ) linked by 
disulfide bonds. Mutations in β-fibrinogen gene lead to 
thrombotic tendency. The fibrinogen-raising beta-
fibrinogen gene -455G/A polymorphism may enhance the 
physiological increase in fibrinogen levels during 
pregnancy and thereby may predispose to obstetric 
complications (Leander et al., 2002). 
Human platelets carry membrane glycοproteins that 
control platelet aggregation and activation. A number of 
clinical studies have suggested that certain polymorphisms 
of genes encοding these proteins increase the risk for 
thrombosis (Chiras et al., 2009). Human platelet antigen-1 
"HPA-1", GpIIIa or Integrin Beta-3 is a platelet membrane 
glycoprotein encoded by ITGB3 gene. The common 
polymorphism T196C in this gene results in a L59P 
substitution and is described as the PLA1/A2 alloantigen 
system (Chiras et al., 2009; Tan et al., 2012).  
Studies on prevalence of beta-fibrinogen -455G/A 
polymorphism among patients with RPL in different 
populations have yielded conflicting results, whereas 
some investigators showed an association between this 
polymorphism and RPL (Goodman et al., 2006; Ticconi 
et al., 2011; Jeddi-Tehrani et al., 2011; Torabi et al., 
2012) others, however, reported the lack of a meaningful 
association (e.g., Pihusch et al., 2001; Coulam et al., 
2006; Yenicesu et al., 2010; Ozdemir et al., 2011) 
The trend is not different for ITGB3 PLA1/A2 
polymorphism as some authors stated that this 
polymorphism constitute a risk factor for RPL (Ruzzi et 
al., 2005; Ivanov et al., 2010; Lambrinoudaki et al., 2010; 
Yenicesu et al., 2010; Goncharova et al., 2013), other 
studies did not confirm such a relation (Pihusch et al., 
2001; Ozdemir et al., 2011). 
This study was performed in order to investigate the 
relation between RPL and the common polymorphisms in 
β-fibrinogen (-455 G>A; "rs1800790") and Integrin beta-
3 a/b (PLA1/A2; "rs5918") genes among Palestinian RPL 
women residing in Gaza Strip. 
METHODS 
Study population 
The study was conducted on 102 Palestinian women, 18–
35 years old, from Gaza strip who had at least two RPLs 
≤20 weeks of gestation. Age and ethnicity matched 97 
women with at least two live births and without a 
previous history of abortion or pregnancy-associated 
complications served as the control group. Informed 
consent was obtained from all participants, and approval 
for conducting the study was obtained from the local 
ethics committee. 
DNA extraction and polymorphism determination 
Genomic DNA was extracted from EDTA-blood samples 
using Wizard Genomic DNA purification Kit (Promega, 
USA) following the manufacturer’s instructions. 
Genotyping was performed using polymerase chain 
reaction (PCR) and restriction length fragment 
polymorphism (RLFP) for β-fibrinogen - 455G>A and 
sequence-specific (PCR-SSP) for ITGB3 PLA1/A2.  
The PCR primers (Table I), restriction enzyme and PCR 
conditions employed in genotyping β-fibrinogen -
455G>A were carried out as described by Xiang-feng et 
al. (2008). The polymorphism was defined by digesting 
the PCR product with the restriction endonuclease HaeIII 
(New England BioLabs) at 37°C for 16 hrs. The 
polymorphic A allele PCR product remains uncut (336-
bp) whereas, the wild type G allele is cut into two 
fragments of 215 and 121-bp.  
The ITGB3 PLA1/A2 polymorphism was determined by 
PCR-SSP as described by Chiras et al. (2009) using the 
primers shown in Table 2. 
Statistical analysis  
The Hardy-Weinberg equilibrium (HWE) equation was 
used to calculate the expected genotypes frequencies. 
Difference between expected and observed genotypes 
was assessed by Chi square (X
2
) test. P-values less than 
0.05 were considered statistically significant. The 
frequencies of the alleles and genotypes were compared 
between patient and control groups by X
2
 test. The odds 
ratio (OR) and 95% confidence interval (CI) were also 
estimated in order to test the relation between RPL and 
the investigated polymorphisms. 
RESULTS 
-455G>A fibrinogen gene polymorphism and RPL 
Genotype and allele frequencies of -455G>A fibrinogen 
gene polymorphism were not significantly different 
between RPL patients and controls (Table 3). Moreover, 
statistical analyses of the genotypes under both recessive 
and dominant models (data no shown) revealed no 
significant difference between the two study groups.  
PLA1/A2 ITGB3 gene polymorphism and RPL  
Genotype and allele frequencies of PLA1/A2 ITGB3 gene 
polymorphism were not significantly different between 
RPL patients and controls (Table 4). Additionally, 
statistical analyses of the genotypes under both recessive 
and dominant models (data not shown) indicated no 
significant difference between RPL and control groups.  
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Table 1: Primer sequences and restriction enzyme for -455G>A fibrinogen. 






336 bp HaeIII 
A allele 336 bp 
G allele 215+121 bp 




Common forward                              5’ GGAGGTAGAGAGTCGCCATAG 3’  
PLA1 specific reverse primer 5’ TCACAGCGAGGTGAGGCCA 3’ 90 
PLA2 specific reverse primer 5’ TCACAGCGAGGTGAGGCCG 3’ 90 






Odds Ratio (95% CI) P-value 
fibrinogen 
-455G>A 
GG 70 (68.6%) 62 (63.9%) 1.23 (0.69-2.22) 0.48 
GA 28 (27.5%) 31 (32.0%) 0.81 (0.44-1.48) 0.49 







0.85 (0.52-1.41) 0.53 













A1/A1 70 (68.6%) 62 (63.9%) 1.23 (0.68-2.22) 0.48 
A1/A2 30 (29.4%) 33 (34.0%) 0.81 (0.44-1.47) 0.48 







1.18 (0.71-1.97) 0.53 
 
Hardy-Weinberg equilibrium 
Analysis of the observed and the calculated expected 
genotype frequencies of β-fibrinogen 455G>A and 
ITGB3 PLA1/A2 polymorphisms in the control group 
showed that the distribution of both genes' genotypes are 
in Hardy-Weinberg equilibrium. 
DISCUSSION 
Normal pregnancy is inherently a hypercoagulable state 
where it is associated with an increase in various 
physiologic coagulants and a decrease in natural 
anticoagulants (Brenner et al., 2006; Cernecab et al., 
1997). Genetic variation in any of the several loci 
involved in the coagulation/fibrinolysis system may 
further exacerbate this hypercoagulability and result in 
intervillous or spiral-artery thrombosis, inadequate 
placental perfusion and could lead to miscarriage (Ford 
and Schust, 2009). This theory is solidified by the fact 
that many thrombophilia-associated RPL cases have been 
successfully treated with administering appropriate 
anticoagulants (Gris et al., 2004; Brenner et al., 2005). 
β-fibrinogen and ITGB3 proteins are components of the 
coagulation system and common polymorphisms in the 
genes (-455G/A and PLA1/A2, respectively) encoding 
those proteins have been linked with thrombophilia and 
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increased risk of RPL (Goodman et al., 2006; Ticconi et 
al., 2011; Jeddi-Tehrani et al., 2011; Torabi et al., 2012; 
Ruzzi et al., 2005; Ivanov et al., 2010; Lambrinoudaki et 
al., 2010; Yenicesu et al., 2010; Goncharova et al., 2013). 
Our findings, however, did not replicate this association 
and revealed that these two polymorphisms do not 
represent a risk factor for RPL in our population. 
Meanwhile, results of the present study are in agreement 
with other reports that also showed lack of association 
between RPL and -455G/A and PLA1/A2 (Pihusch et al., 
2001; Coulam et al., 2006; Yenicesu et al., 2010; Ozdemir 
et al., 2011).  
Discrepancy between results of association studies 
conducted on various populations could be due to many 
reasons including study sample characteristics, 
population genetic variation(s) unrelated to investigated 
polymorphism(s), presence of nucleotide polymorphism 
somewhere else in, or in the vicinity of, the investigated 
loci, epigenetic alterations and linkage disequilibrium to 
other sequence variants.  
Some authors, due to the multifactorial nature of at least 
40-50% the RPL cases, proposed that thrombophilia risk 
alleles should not be tested individually but as part of a 
panel of multiple gene variants (Coulam et al., 2006; 
Goodman et al., 2006; Torabi et al., 2012; ). Despite our 
agreement on that proposition we still believe that each 
allele in this panel, when tested alone, should show 
significant difference between RPL patients and control 
subjects. Furthermore, no international consensus will be 
attained on the component polymorphisms of such a 
panel and perhaps each population will have its own 
particular panel.  
In light of the obtained results we do not recommend 
inclusion of β-fibrinogen -455G/A and ITGB3 PLA1/A2 
polymorphisms when screening idiopathic RPL cases for 
inherited thrombophilia in our population. 
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